Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Squashes Sprout's Attempt To Remove Boxed Warning From Addyi Label

Apr 14 2019

• By Brenda Sandburg

Female Viagra

Related Content

Keeping Track: A Week Of Calm As Shutdown Drags On

Jan 12 2019

Valeant Returns $1bn Female Libido Drug For Free

Nov 07 2017

In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication

Jun 08 2015

Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed

Jun 05 2015

FDA Reviewers Disagreed About Approval Of Sprout's Addyi

Dec 14 2015

Related Companies

Sprout Pharmaceuticals, Inc.

AMAG Pharmaceuticals Inc.

Boehringer Ingelheim GmbH

Bausch Health Companies Inc.

Additional Topics

United States Drug Safety Post Market Regulation & Studies Regulation Commercial FDA Neurology BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window